U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H12N2O2
Molecular Weight 252.268
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OXCARBAZEPINE

SMILES

NC(=O)N1C2=C(CC(=O)C3=C1C=CC=C3)C=CC=C2

InChI

InChIKey=CTRLABGOLIVAIY-UHFFFAOYSA-N
InChI=1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)

HIDE SMILES / InChI

Molecular Formula C15H12N2O2
Molecular Weight 252.268
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Oxcarbazepine and its active metabolite (10,11-dihydro-10-hydroxy-carbazepine, MHD) have been effective in animal models of epilepsy that generally predict efficacy in generalized tonic-clonic seizures and partial seizures in humans. The pharmacokinetic profile of oxcarbazepine is less complicated than that of carbamazepine, with less metabolism by the cytochrome P450 system, no production of an epoxide metabolite, and lower plasma protein binding. The clinical efficacy and tolerability of oxcarbazepine have been demonstrated in trials in adults, children, and the elderly. The pharmacological activity of oxcarbazepine is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine. The precise mechanism by which oxcarbazepine and MHD exert their antiseizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
TRILEPTAL

Approved Use

Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4 years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with partial seizures. Oxcarbazepine tablet is an antiepileptic drug indicated for: Adults: -Monotherapy or adjunctive therapy in the treatment of partial seizures Children: -Monotherapy in the treatment of partial seizures in children 4-16 years -Adjunctive therapy in the treatment of partial seizures in children 2-16 years (1)

Launch Date

9.4780798E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.55 μg/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7119 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
9349.83 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
1630.3 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
3537.63 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3.76 μg × h/mL
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
157372 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
179002.4 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
173770 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
197864.34 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
LICARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
5309.5 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
9445.55 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
5873.1 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fasted
9679.79 ng*h/mL
600 mg single, oral
dose: 600 mg
route of administration: oral
experiment type: single
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population:
age:
sex:
food status: Fed
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.38 h
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
300 mg 2 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OXCARBAZEPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Disc. AE: Convulsions, Status epilepticus...
AEs leading to
discontinuation/dose reduction:
Convulsions (3.7%)
Status epilepticus (1.2%)
Ataxia (1.2%)
Sources:
15 g single, oral
Overdose
Dose: 15 g
Route: oral
Route: single
Dose: 15 g
Sources:
unhealthy, 13 years
n = 1
Health Status: unhealthy
Age Group: 13 years
Sex: M
Population Size: 1
Sources:
Other AEs: Vomiting...
Other AEs:
Vomiting (1 patient)
Sources:
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Other AEs: Dizziness, Tremor...
Other AEs:
Dizziness
Tremor
Somnolence
Headache
Sources:
30600 mg single, oral
Overdose
Dose: 30600 mg
Route: oral
Route: single
Dose: 30600 mg
Sources:
unhealthy, 36 years
n = 1
Health Status: unhealthy
Age Group: 36 years
Sex: M
Population Size: 1
Sources:
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Disc. AE: Somnolence, Vomiting...
AEs leading to
discontinuation/dose reduction:
Somnolence (2.4%)
Vomiting (2%)
Ataxia (1.8%)
Diplopia (1.3%)
Dizziness (1.3%)
Fatigue (1.1%)
Nystagmus (1.1%)
Sources:
12 mg/kg 1 times / day steady, oral (starting)
Dose: 12 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
n = 1
Health Status: unhealthy
Condition: f benign rolandic epilepsy
Age Group: 6 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Stevens Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Stevens Johnson syndrome (1 patient)
Sources:
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1524
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 1524
Sources:
Disc. AE: Hyponatremia...
AEs leading to
discontinuation/dose reduction:
Hyponatremia (2.5%)
Sources:
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Disc. AE: Dizziness, Diplopia...
AEs leading to
discontinuation/dose reduction:
Dizziness (6.4%)
Diplopia (5.9%)
Ataxia (5.2%)
Vomiting (5.1%)
Nausea (4.9%)
Somnolence (3.8%)
Headache (2.9%)
Fatigue (2.1%)
Abnormal vision (2.1%)
Tremor (1.8%)
Abnormal gait (1.7%)
Rash (1.4%)
Hyponatremia (1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Ataxia 1.2%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Status epilepticus 1.2%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Convulsions 3.7%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 1 month -4 years
n = 241
Health Status: unhealthy
Condition: partial seizures
Age Group: 1 month -4 years
Population Size: 241
Sources:
Vomiting 1 patient
15 g single, oral
Overdose
Dose: 15 g
Route: oral
Route: single
Dose: 15 g
Sources:
unhealthy, 13 years
n = 1
Health Status: unhealthy
Age Group: 13 years
Sex: M
Population Size: 1
Sources:
Dizziness
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Headache
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Somnolence
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Tremor
2700 mg 1 times / day multiple, oral
Highest studied dose
Dose: 2700 mg, 1 times / day
Route: oral
Route: multiple
Dose: 2700 mg, 1 times / day
Sources:
unhealthy, 19-70 years
n = 71
Health Status: unhealthy
Age Group: 19-70 years
Sex: M+F
Population Size: 71
Sources:
Fatigue 1.1%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Nystagmus 1.1%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Diplopia 1.3%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Dizziness 1.3%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Ataxia 1.8%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Vomiting 2%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Somnolence 2.4%
Disc. AE
8 mg/kg 1 times / day steady, oral (starting)
Recommended
Dose: 8 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg/kg, 1 times / day
Sources:
unhealthy, 4-16 years
n = 456
Health Status: unhealthy
Condition: partial seizures
Age Group: 4-16 years
Population Size: 456
Sources:
Stevens Johnson syndrome 1 patient
Disc. AE
12 mg/kg 1 times / day steady, oral (starting)
Dose: 12 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 12 mg/kg, 1 times / day
Sources:
unhealthy, 6 years
n = 1
Health Status: unhealthy
Condition: f benign rolandic epilepsy
Age Group: 6 years
Sex: M
Population Size: 1
Sources:
Hyponatremia 2.5%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1524
Health Status: unhealthy
Condition: epilepsy
Age Group: adult
Population Size: 1524
Sources:
Hyponatremia 1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Rash 1.4%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Abnormal gait 1.7%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Tremor 1.8%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Abnormal vision 2.1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Fatigue 2.1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Headache 2.9%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Somnolence 3.8%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Nausea 4.9%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Vomiting 5.1%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Ataxia 5.2%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Diplopia 5.9%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Dizziness 6.4%
Disc. AE
300 mg 2 times / day steady, oral (starting)
Recommended
Dose: 300 mg, 2 times / day
Route: oral
Route: steady
Dose: 300 mg, 2 times / day
Sources:
unhealthy, adult
n = 1537
Health Status: unhealthy
Condition: partial seizures
Age Group: adult
Population Size: 1537
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive [Activation 39.8107 uM]
likely
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [Ki 1150 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1350 uM]
no [Ki >1800 uM]
no [Ki >1800 uM]
no [Ki >900 uM]
no [Ki >900 uM]
weak [Ki 270 uM]
weak [Ki 647 uM]
weak
yes [Ki 228 uM]
yes [Ki 88 uM]
yes
yes
yes
yes
yes (co-administration study)
Comment: Coadministration of OXCARBAZEPINE decreased the AUC for Felodipine and Ethinylestradiol (both CYP3A4 substrate)
Page: (Pharm) 19, (Label) 18
Drug as victim
PubMed

PubMed

TitleDatePubMed
Suppressive effects of oxcarbazepine on tooth pulp-evoked potentials recorded at the trigeminal spinal tract nucleus in cats.
2001 Mar
Symptomatic trigeminal-autonomic cephalalgia evolving to trigeminal neuralgia: report of a case associated with dual pathology.
2001 Nov
Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.
2002
What do you do when they grow up? Approaches to seizures in developmentally delayed adults.
2002
Interactions between antiepileptic drugs and hormonal contraception.
2002
Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications.
2002
Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents.
2002
Anticonvulsants: aspects of their mechanisms of action.
2002
The 'number needed to treat' with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).
2002 Apr
Gabapentin: new indication. Little impact on partial epilepsy in children between 3 and 12.
2002 Apr
Oxcarbazepine and hepatic porphyria.
2002 Apr
Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone.
2002 Aug
Women with PTSD: the psychodynamic aspects of psychopharmacologic and "hands-on" psychiatric management.
2002 Fall
Oxcarbazepine treatment of refractory bipolar disorder: a retrospective chart review.
2002 Feb
Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.
2002 Feb
Pediatric partial and generalized seizures.
2002 Jan
Using the new antiepilepsy drugs in children.
2002 Jan
Three new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide.
2002 Jan
Oxcarbazepine.
2002 Jan
Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry.
2002 Jul
Gateways to clinical trials.
2002 Jul-Aug
Gateways to Clinical Trials. June 2002.
2002 Jun
Oxcarbazepine for epilepsy--a useful new choice?
2002 Jun
Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication.
2002 Jun
Some common issues in the use of antiepileptic drugs.
2002 Mar
Effects of oxcarbazepine on sodium concentration and water handling.
2002 May
[New antiepileptic drugs: new therapeutic options].
2002 May
LC determination of oxcarbazepine and its active metabolite in human serum.
2002 May 15
Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects.
2002 Nov
Oxcarbazepine for mood disorders.
2002 Oct
[Monitoring serum levels of new antiepileptics].
2002 Sep
[Characteristics and indications of oxcarbazepine].
2002 Sep
Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).
2002 Sep
Octakis-6-sulfato-gamma-cyclodextrin as additive for capillary electrokinetic chromatography of dibenzoazepines: carbamazepine, oxcarbamazepine and their metabolites.
2002 Sep
Use of anticonvulsants for treatment of neuropathic pain.
2002 Sep 10
Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study.
2002 Sep 24
Pharmacokinetics of mood stabilizers and new anticonvulsants.
2002 Winter
Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
2003 Jul
Overview of the clinical pharmacokinetics of oxcarbazepine.
2004
Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans.
2004 Aug
Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy.
2005 Dec 15
A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine.
2005 Oct
Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV.
2006 Jan
Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection.
2007 Jul 16
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma.
2007 Jun
Stereoselective disposition of S- and R-licarbazepine in mice.
2008 Jun
Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food.
2008 May
Eyeblink conditioning anomalies in bipolar disorder suggest cerebellar dysfunction.
2009 Feb
Binding of licarbazepine enantiomers to mouse and human plasma proteins.
2010 Jul
Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma.
2010 Jun
Patents

Sample Use Guides

Bipolar I Disorder: 750- 2000 mg/day
Route of Administration: Oral
Free and bound fractions of S-licarbazepine (S-Lic) and R-licarbazepine (R-Lic) were separated by ultrafiltration after previous in vitro incubation of spiked plasma samples and protein solutions with each enantiomer at 10, 25 and 50 ug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:08 UTC 2023
Edited
by admin
on Fri Dec 15 15:06:08 UTC 2023
Record UNII
VZI5B1W380
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OXCARBAZEPINE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
OXCARBAZEPINE [VANDF]
Common Name English
TRILEPTAL
Common Name English
oxcarbazepine [INN]
Common Name English
OXCARBAMAZEPINE
Common Name English
OXCARBAZEPINE [HSDB]
Common Name English
OXCARBAZEPINE [USP MONOGRAPH]
Common Name English
KIN-493
Code English
OXCARBAZEPINE [USAN]
Common Name English
OXCARBAZEPINE [MI]
Common Name English
OXCARBAZEPINE [JAN]
Common Name English
GP-47680
Code English
Oxcarbazepine [WHO-DD]
Common Name English
NSC-758693
Code English
OXCARBAZEPINE [EP MONOGRAPH]
Common Name English
SPN-804
Code English
10,11-DIHYDRO-10-OXO-5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
Systematic Name English
OXCARBAZEPINE [ORANGE BOOK]
Common Name English
OXCARBAZEPINE [USP-RS]
Common Name English
OXCARBAZEPINE [MART.]
Common Name English
5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE, 10,11-DIHYDRO-10-OXO-
Systematic Name English
OXTELLAR XR
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C264
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
LIVERTOX NBK548414
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
NDF-RT N0000008486
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
NDF-RT N0000175753
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
WHO-VATC QN03AF02
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
WHO-ATC N03AF02
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
Code System Code Type Description
DRUG BANK
DB00776
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
CAS
28721-07-5
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
EVMPD
SUB32960
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
INN
4585
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
WIKIPEDIA
OXCARBAZEPINE
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
EVMPD
SUB09510MIG
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
USAN
MM-02
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
HSDB
7524
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
LACTMED
Oxcarbazepine
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
IUPHAR
7254
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
ECHA (EC/EINECS)
249-188-8
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
DAILYMED
VZI5B1W380
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
MESH
C036006
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
RS_ITEM_NUM
1483152
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
FDA UNII
VZI5B1W380
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
DRUG CENTRAL
2017
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
RXCUI
32624
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY RxNorm
NSC
758693
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
SMS_ID
100000092224
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
PUBCHEM
34312
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
CHEBI
7824
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
MERCK INDEX
m8298
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID0045703
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
ChEMBL
CHEMBL1068
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
NCI_THESAURUS
C47643
Created by admin on Fri Dec 15 15:06:08 UTC 2023 , Edited by admin on Fri Dec 15 15:06:08 UTC 2023
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> INHIBITOR
Ki
METABOLIC ENZYME -> INDUCER
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ki
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
BINDER->LIGAND
BINDING
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
METABOLIC ENZYME -> INDUCER
Ki
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
sum of impurities K and L: maximum 0.1 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
sum of impurities K and L: maximum 0.1 per cent
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC FASTED CONDITION

SINGLE DOSE ADMINISTRATION

HEALTHY MALE SUBJECTS

Volume of Distribution PHARMACOKINETIC MHD
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC MHD
PHARMACOKINETIC
Extended Release; Parent drug
PHARMACOKINETIC
Immediate release; Parent drug
PHARMACOKINETIC
MHD
PHARMACOKINETIC
Immediate release; MHD
PHARMACOKINETIC